Search research articles
Contact Us
Filters
Showing results (61-70 of 350) with videos related to
Page
of 35
Sort By:
Case Reports in Urology
|
October 4, 2021
The Intraoperative Use of a Portable Cone-Beam Computed Tomography System for the Diagnosis of Intraperitoneal Bladder Perforation
Ankur Choksi, Benjamin Press, Cayce Nawaf, et al.
Pharmaceutics
|
October 23, 2021
Model-Informed Precision Dosing during Infliximab Induction Therapy Reduces Variability in Exposure and Endoscopic Improvement between Patients with Ulcerative Colitis
Ruben Faelens, Zhigang Wang, Thomas Bouillon, et al.
Intestinal Research
|
June 30, 2025
Ulcerative colitis disease severity affects the speed of symptom relief under filgotinib treatment: a post hoc analysis of the phase 2b/3 SELECTION study
Masayuki Saruta, Silvio Danese, Yoshie Takatori, et al.
BMJ Open Gastroenterology
|
February 6, 2023
Distinct transcriptional signatures in purified circulating immune cells drive heterogeneity in disease location in IBD
Bram Verstockt, Sare Verstockt, Jonathan Cremer, et al.
Journal of Gastroenterology and Hepatology
|
December 28, 2018
Immunogenicity is not the driving force of treatment failure in vedolizumab-treated inflammatory bowel disease patients
Nathalie Van den Berghe, Bram Verstockt, Sophie Tops, et al.
Alimentary Pharmacology & Therapeutics
|
April 20, 2022
Safety of sequential biological therapy in inflammatory bowel disease: results from a tertiary referral centre
Annick Moens, Nasim Sadat Seyed Tabib, Vera Ballet, et al.
Journal of Crohn'S & Colitis
|
January 25, 2022
Introduction of Subcutaneous Infliximab CT-P13 and Vedolizumab in Clinical Practice: A Multi-Stakeholder Position Statement Highlighting the Need for Post-Marketing Studies
Liselotte Fierens, Claire Liefferinckx, Eveline Hoefkens, et al.
Inflammatory Bowel Diseases
|
November 9, 2022
Screening Failure in a Large Clinical Trial Centre for Inflammatory Bowel Diseases: Rates, Causes, and Outcomes
An Outtier, Liese Gijbels, Maja Noman, et al.
Inflammatory Bowel Diseases
|
December 14, 2020
Understanding the Molecular Drivers of Disease Heterogeneity in Crohn's Disease Using Multi-omic Data Integration and Network Analysis
Padhmanand Sudhakar, Bram Verstockt, Jonathan Cremer, et al.
British Journal of Clinical Pharmacology
|
July 1, 2021
Population pharmacokinetic-pharmacodynamic model-based exploration of alternative ustekinumab dosage regimens for patients with Crohn's disease
Zhigang Wang, Bram Verstockt, João Sabino, et al.
Page
of 35
Search research articles
Search
Showing results (61-70 of 350) with videos related to
Sort By:
Page
of 35
Case Reports in Urology
|
October 4, 2021
The Intraoperative Use of a Portable Cone-Beam Computed Tomography System for the Diagnosis of Intraperitoneal Bladder Perforation
Ankur Choksi, Benjamin Press, Cayce Nawaf, et al.
Pharmaceutics
|
October 23, 2021
Model-Informed Precision Dosing during Infliximab Induction Therapy Reduces Variability in Exposure and Endoscopic Improvement between Patients with Ulcerative Colitis
Ruben Faelens, Zhigang Wang, Thomas Bouillon, et al.
Intestinal Research
|
June 30, 2025
Ulcerative colitis disease severity affects the speed of symptom relief under filgotinib treatment: a post hoc analysis of the phase 2b/3 SELECTION study
Masayuki Saruta, Silvio Danese, Yoshie Takatori, et al.
BMJ Open Gastroenterology
|
February 6, 2023
Distinct transcriptional signatures in purified circulating immune cells drive heterogeneity in disease location in IBD
Bram Verstockt, Sare Verstockt, Jonathan Cremer, et al.
Journal of Gastroenterology and Hepatology
|
December 28, 2018
Immunogenicity is not the driving force of treatment failure in vedolizumab-treated inflammatory bowel disease patients
Nathalie Van den Berghe, Bram Verstockt, Sophie Tops, et al.
Alimentary Pharmacology & Therapeutics
|
April 20, 2022
Safety of sequential biological therapy in inflammatory bowel disease: results from a tertiary referral centre
Annick Moens, Nasim Sadat Seyed Tabib, Vera Ballet, et al.
Journal of Crohn'S & Colitis
|
January 25, 2022
Introduction of Subcutaneous Infliximab CT-P13 and Vedolizumab in Clinical Practice: A Multi-Stakeholder Position Statement Highlighting the Need for Post-Marketing Studies
Liselotte Fierens, Claire Liefferinckx, Eveline Hoefkens, et al.
Inflammatory Bowel Diseases
|
November 9, 2022
Screening Failure in a Large Clinical Trial Centre for Inflammatory Bowel Diseases: Rates, Causes, and Outcomes
An Outtier, Liese Gijbels, Maja Noman, et al.
Inflammatory Bowel Diseases
|
December 14, 2020
Understanding the Molecular Drivers of Disease Heterogeneity in Crohn's Disease Using Multi-omic Data Integration and Network Analysis
Padhmanand Sudhakar, Bram Verstockt, Jonathan Cremer, et al.
British Journal of Clinical Pharmacology
|
July 1, 2021
Population pharmacokinetic-pharmacodynamic model-based exploration of alternative ustekinumab dosage regimens for patients with Crohn's disease
Zhigang Wang, Bram Verstockt, João Sabino, et al.
Page
of 35